Structure Therapeutics, also known as GPCR, has experienced sharp swings and a strong one year return in its valuation. The company has recently had positive phase 2 data and a large capital raise, and has also begun a first-in-human trial for its obesity candidate ACCG-2671. The valuation of Structure Therapeutics is being assessed in light of these developments.